secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001606498-25-000087
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs
--------------------------------------------------------------------------------

- Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.
- Net income $6.6M ($0.14 diluted EPS) vs $0.5M ($0.01) a year ago; adjusted net income $12.0M ($0.26 adjusted EPS).
- SNS segment net sales $101.1M with 8.7% volume growth driven by enteral feeding and neonate solutions.
- PM&R segment net sales $56.2M; RFA product sales grew 8.2% from ESENTEC/TRIDENT momentum.
- 2025 revenue guidance reaffirmed at $665-$685M; adjusted EPS guidance lowered to $0.75-$0.95 due to tariff impacts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000087/0001606498-25-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000087/avns-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001606498-25-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer